Adocia S.A.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ADOCY research report →
Companywww.adocia.com
Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform is designed and developed to optimize the performance of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide.
- CEO
- Olivier Soula
- IPO
- 2014
- Employees
- 78
- HQ
- Lyon, FR
Price Chart
Valuation
- Market Cap
- $170.44M
- P/E
- -6.02
- P/S
- 67.53
- P/B
- 66.94
- EV/EBITDA
- -5.94
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -1213.97%
- Op Margin
- -1229.56%
- Net Margin
- -1124.81%
- ROE
- -3796.57%
- ROIC
- -152.98%
Growth & Income
- Revenue
- $1.42M · -84.80%
- Net Income
- $-15,936,197 · -70.97%
- EPS
- $-0.81 · 16.49%
- Op Income
- $-17,421,181
- FCF YoY
- 0.00%
Performance & Tape
- 52W High
- $11.80
- 52W Low
- $11.80
- 50D MA
- $11.80
- 200D MA
- $11.80
- Beta
- 0.86
- Avg Volume
- 112
Get TickerSpark's AI analysis on ADOCY
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ADOCY Coverage
We haven't published any research on ADOCY yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ADOCY Report →